AMIX · Autonomix Medical, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q3 '26 | Q2 '26 | Q1 '25 | Q3 '25 | Q2 '24 | Q1 '24 | Q3 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | - | $0 | $0 | $0 | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| R&D | $1.59M | $1.72M | $2.37M | - | $1.04M | $471.0K | $954.0K | $199.0K | - |
| SG&A | $1.83M | $1.62M | $5.17M | - | $1.70M | $793.0K | $1.80M | $2.32M | - |
| Total Operating Expenses | $3.42M | $3.34M | $7.53M | - | $2.75M | $2.84M | $2.75M | $544.0K | - |
| D&A | $3.0K | - | - | - | - | - | $43.0K | - | - |
| Operating Income | ($3.42M) | ($3.34M) | ($7.53M) | - | ($2.75M) | ($5.82M) | ($2.75M) | ($544.0K) | - |
| Interest Expense | $0 | $0 | $0 | - | $100.0K | $0 | $41.0K | $0 | - |
| Income Tax | $0 | $0 | $0 | - | $0 | $0 | $0 | $0 | - |
| Net Income | ($3.34M) | ($3.26M) | ($7.45M) | - | ($2.71M) | ($2.81M) | ($2.70M) | ($6.04M) | - |
| EPS - Basic | ($1.07) | ($0.36) | ($1.38) | - | ($1.46) | ($8.78) | ($0.07) | ($0.05) | - |
| EPS - Diluted | - | - | - | - | - | - | - | ($0.05) | - |
Balance Sheet
| Line item | Q1 '26 | Q3 '26 | Q2 '26 | Q1 '25 | Q3 '25 | Q2 '24 | Q1 '24 | Q3 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.00M | $9.93M | $7.48M | $9.14M | $11.82M | $5.16M | $6.75M | $810.0K | $865.0K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $700.0K | $714.0K | $842.0K | $676.0K | $232.0K | $574.0K | $287.0K | $173.0K | - |
| Current Assets | $7.58M | $10.19M | $7.89M | $9.61M | $11.93M | $5.35M | $7.08M | $865.0K | - |
| Total Assets | $7.60M | $10.21M | $7.93M | $9.81M | $11.95M | $5.37M | $7.09M | $1.81M | - |
| Current Liabilities | $1.71M | $1.65M | $1.49M | $1.71M | $2.25M | $1.26M | $763.0K | $973.0K | - |
| Long-term Debt | - | - | - | - | - | - | - | $1.46M | - |
| Total Liabilities | $1.71M | $1.65M | $1.49M | $1.71M | $2.25M | $2.34M | $1.81M | $7.40M | - |
| Stockholders' Equity | $5.89M | $8.56M | $6.45M | $8.10M | $9.71M | $3.03M | $5.29M | $644.0K | - |
| Retained Earnings | ($67.09M) | ($64.43M) | ($61.17M) | ($50.38M) | ($47.19M) | ($44.48M) | ($41.67M) | ($33.56M) | - |
Cash Flow
| Line item | Q1 '26 | Q3 '26 | Q2 '26 | Q1 '25 | Q3 '25 | Q2 '24 | Q1 '24 | Q3 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.60M) | - | - | - | - | - | ($661.0K) | - | - |
| Investing Cash Flow | $0 | - | - | - | - | - | ($5.0K) | - | - |
| Financing Cash Flow | $2.06M | - | - | - | - | - | $2.73M | - | - |
| CapEx | $0 | - | - | - | - | - | $0 | - | - |
| Free Cash Flow | ($2.60M) | - | - | - | - | - | ($661.0K) | - | - |
Ratios
| Metric | Q1 '26 | Q3 '26 | Q2 '26 | Q1 '25 | Q3 '25 | Q2 '24 | Q1 '24 | Q3 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||
| Gross margin | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.78 | - | - | - | - | - | 0.24 | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - |
| Return on assets | -43.9% | -31.9% | -93.9% | - | -22.7% | -52.3% | -38.0% | -333.9% | - |
| Return on equity | -56.6% | -38.1% | -115.6% | - | -27.9% | -92.7% | -51.0% | -937.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | -20.5% | - |
| Liquidity | |||||||||
| Current ratio | 4.45 | 6.18 | 5.31 | 5.63 | 5.31 | 4.26 | 9.27 | 0.89 | - |
| Quick ratio | 4.45 | 6.18 | 5.31 | 5.63 | 5.31 | 4.26 | 9.27 | 0.89 | - |
| Cash ratio | 4.11 | 6.02 | 5.03 | 5.35 | 5.27 | 4.10 | 8.85 | 0.83 | - |
| Leverage | |||||||||
| Debt / Equity | - | - | - | - | - | - | - | 2.26 | - |
| Debt / Assets | - | - | - | - | - | - | - | 0.81 | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | -27.5x | - | -67.1x | - | - |
| Equity multiplier | 1.29 | 1.19 | 1.23 | 1.21 | 1.23 | 1.77 | 1.34 | 2.81 | - |
| Liabilities / Assets | 0.22 | 0.16 | 0.19 | 0.17 | 0.19 | 0.44 | 0.25 | 4.09 | - |
| Efficiency | |||||||||
| Asset turnover | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - |
| Valuation | |||||||||
| P / E | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - |
| Growth | |||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | -21.7% | - | - | -405.0% | - | - | - | - |
| Net income growth (YoY) | - | -20.2% | - | - | 55.1% | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -27.2% | -11.8% | - | 53.1% | 1407.3% | - | - | - | - |
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Autonomix Medical against the 5 most active filers in the same SIC group.